[1]王艳,苏峰,李园园,等.蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究.实用肝脏病杂志,2019,22(4):474-477. [2]张胥磊,杨庆余,韩秋玉,等.自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化.实用肝脏病杂志,2019,22(5):660-663. [3]Cai J, Zhang XJ, Li H. Role of innate immune signaling in non-alcoholic fatty liver disease. Trends Endocrinol Metab, 2018, 29(10): 712-722. [4]Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol, 2017, 23(36): 6549. [5]Chaphalkar R, Apte KG, Talekar Y, et al. Antioxidants of Phyllanthus emblica L. bark extract provide hepatoprotection against ethanol-induced hepatic damage: a comparison with silymarin. Oxid Med Cell Longev, 2017, 2017: 3876040. [6]Dinesh M, Roopan SM, Selvaraj CI, et al. Phyllanthus emblica seed extract mediated synthesis of PdNPs against antibacterial, heamolytic and cytotoxic studies. J Photochem Photobiol A Chem, 2017, 167: 64-71. [7]Leoni S, Tovoli F, Napoli L, et al. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol, 2018, 24(30): 3361. [8]Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD)–pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev, 2017, 49(2): 197-211. [9]Zhu JZ, Zhou QY, Wang YM, et al. Prevalence of fatty liver disease and the economy in China: a systematic review. World J Gastroenterol, 2015, 21(18): 5695. [10]Zhang M, Yuan Y, Wang Q, et al. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα. Biosci Rep, 2018, 38(6): BSR20180644. [11]Liang Y, Zhang Y, Deng Y, et al. Chaihu-Shugan-San decoction modulates intestinal microbe dysbiosis and alleviates chronic metabolic inflammation in NAFLD rats via the NLRP3 inflammasome pathway. Evid Based Complement Alternat Med, 2018, 2018:9390786. [12]He B, Wu L, Xie W, et al. The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol, 2017, 18(1): 33. [13]程雪,单永业,罗亚文.Th17/调节性T淋巴细胞比率在急性乙型肝炎患者外周血的动态变化及其意义.中华肝脏病杂志,2016,24(8):565-568. [14]Li Y, Jiang HT, Han LB, et al. MiR-195 regulates CD40 to maintain Th17/Treg balance in rats with non-alcoholic fatty liver disease. Biomed Pharmacother, 2020, 124: 109930. [15]Rau M, Schilling AK, Meertens J, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol, 2016, 196(1): 97-105. [16]Gomes A L, Teijeiro A, Burén S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell, 2016, 30(1): 161-175. [17]Su L, Wu Z, Chi Y, et al. Mesenteric lymph node CD4+ T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease. Cell Immunol, 2019, 337: 33-41. [18]Chackelevicius CM, Gambaro SE, Tiribelli C, et al. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J Gastroenterol, 2016, 22(41): 9096. [19]李红山,陈少东,应豪,等.红景天苷对高脂饮食诱导的大鼠非酒精性脂肪肝肝脏脂肪合成和氧化环节的干预作用.中华中医药杂志,2017,32(10):4625-4628. [20]Wang D, Lao L, Pang X, et al. Asiatic acid from potentilla chinensis alleviates non-alcoholic fatty liver by regulating endoplasmic reticulum stress and lipid metabolism. Int Immunopharmacol, 2018, 65: 256-267. |